{"entity":{"id":"2005","kind":"year","name":"2005 in oncology","aka":["2005"],"tldr":"Everything OnCo dates to 2005: 135 entries, 37 landmarks, 34 papers listed on people's pages, 24 papers and 14 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"135 dated entries in OnCo fall in 2005: 37 landmarks, 34 papers listed on people's pages, 24 papers, 14 approvals, 7 journals founded, 6 technologies, 5 companies founded, 5 trials reported and 3 regulatory events.\n\nOf those, 3 to the day and 132 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2004","2006"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2005,"events":[{"group":"approval","date":"2005","precision":"year","title":"Bevacizumab approved in EU","note":"Metastatic colorectal cancer with fluoropyrimidine-based chemotherapy. Avastin marketing authorisation issued 12 January 2005.","from":"bevacizumab","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Erlotinib approved in US","note":"Pancreatic cancer with gemcitabine","from":"erlotinib","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Exemestane approved in US","note":"Adjuvant after 2-3 years of tamoxifen","from":"exemestane","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"H101 oncolytic adenovirus approved in CN","note":"Late-stage nasopharyngeal carcinoma, with chemotherapy","from":"h101-oncolytic-adenovirus","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Lenalidomide approved in US","note":"Transfusion-dependent anaemia in low-risk MDS with del(5q)","from":"lenalidomide","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Letrozole (and other aromatase inhibitors) approved in US","note":"Adjuvant early breast cancer (letrozole)","from":"letrozole","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Nab-paclitaxel approved in US","note":"Metastatic breast cancer after combination chemotherapy. FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4","from":"nab-paclitaxel","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Nelarabine approved in US","note":"Relapsed or refractory T-ALL and T-LBL after at least two regimens (accelerated)","from":"nelarabine","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Palifermin approved in EU","note":"Same (Kepivance)","from":"palifermin","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Palonosetron approved in EU","note":"Prevention of chemotherapy-induced nausea and vomiting (Aloxi)","from":"palonosetron","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Recombinant human endostatin approved in CN","note":"Advanced non-small-cell lung cancer, with vinorelbine and cisplatin","from":"recombinant-human-endostatin","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Sorafenib approved in US","note":"Advanced RCC","from":"sorafenib","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"Temozolomide approved in US","note":"Newly diagnosed glioblastoma with radiotherapy","from":"temozolomide","refs":[]},{"group":"approval","date":"2005","precision":"year","title":"UroVysion Bladder Cancer Kit approved in US","note":"Aid to diagnosis of bladder cancer in patients with haematuria","from":"urovysion","refs":[]},{"group":"company","date":"2005","precision":"year","title":"European Myeloma Network founded","note":"Rotterdam","from":"european-myeloma-network","refs":[]},{"group":"company","date":"2005","precision":"year","title":"Founders Fund founded","note":"San Francisco, CA","from":"founders-fund","refs":[]},{"group":"company","date":"2005","precision":"year","title":"Quantum Leap Healthcare Collaborative founded","note":"San Francisco, California, United States","from":"quantum-leap-healthcare-collaborative","refs":[]},{"group":"company","date":"2005","precision":"year","title":"SymBio Pharmaceuticals founded","note":"Tokyo","from":"symbio-pharmaceuticals","refs":[]},{"group":"company","date":"2005","precision":"year","title":"Y Combinator founded","note":"San Francisco, CA","from":"y-combinator","refs":[]},{"group":"history","date":"2005","precision":"year","title":"1p/16q LOH predicts relapse (NWTS-5, Grundy)","note":"Wilms tumour (nephroblastoma)","from":"wilms-tumor","refs":[]},{"group":"history","date":"2005","precision":"year","title":"A gene fusion is found in a common carcinoma","note":"Prostate cancer. Tomlins found TMPRSS2 fused to ERG or ETV1 in 23 of 29 prostate tumours, putting a growth gene under the control of the hormone the prostate lives in.","from":"prostate","refs":["paper-tomlins-tmprss2-ets-fusion-science-2005","erg","tmprss2"]},{"group":"history","date":"2005","precision":"year","title":"A second mutation in the same gene explains resistance","note":"Non-small-cell lung cancer. EGFR T790M is found in a patient relapsing after two years on gefitinib, and independently in progressing tumours that had not carried it before treatme...","from":"nsclc","refs":["paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","egfr-t790m"]},{"group":"history","date":"2005","precision":"year","title":"Adjuvant trastuzumab halves recurrence (HERA, B-31/N9831)","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["hera-b31-n9831"]},{"group":"history","date":"2005","precision":"year","title":"Carboplatin ×1 equals radiotherapy for stage I seminoma (MRC TE19)","note":"Testicular germ cell tumours","from":"testicular","refs":["carboplatin"]},{"group":"history","date":"2005","precision":"year","title":"Curtin and Bastian: distinct genetic pattern with few mutations and many amplifications in acral melanoma","note":"Acral melanoma","from":"acral-melanoma","refs":["kit"]},{"group":"history","date":"2005","precision":"year","title":"D842V shown to confer primary imatinib resistance","note":"PDGFRA D842V-mutant GIST","from":"gist-pdgfra-d842v","refs":["imatinib"]},{"group":"history","date":"2005","precision":"year","title":"HERA, NSABP B-31 and N9831: a year of adjuvant trastuzumab","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["hera-b31-n9831","trastuzumab"]},{"group":"history","date":"2005","precision":"year","title":"HIT-SKK'92: infants with desmoplastic medulloblastoma cured with chemotherapy and no radiotherapy","note":"SHH-activated medulloblastoma","from":"medulloblastoma-shh","refs":["methotrexate"]},{"group":"history","date":"2005","precision":"year","title":"Interferon alfa shown to prolong survival in a retrospective series","note":"Erdheim-Chester disease","from":"erdheim-chester-disease","refs":["interferon-alfa"]},{"group":"history","date":"2005","precision":"year","title":"JAK2 V617F discovered","note":"Myeloproliferative neoplasms (PV, ET, myelofibrosis). Four groups report the mutation in most PV and half of ET/PMF; the first molecular marker for BCR-ABL1-negative MPN.","from":"myeloproliferative-neoplasms","refs":["jak2"]},{"group":"history","date":"2005","precision":"year","title":"JAK2 V617F discovered","note":"Polycythaemia vera (PV). Four groups report the mutation in almost all PV; the first molecular marker for BCR-ABL1-negative MPN and the target for the JAK inhibitors that followed.","from":"polycythaemia-vera","refs":["jak2","jak2-v617f"]},{"group":"history","date":"2005","precision":"year","title":"JAK2 V617F discovered in most polycythaemia vera and half of myelofibrosis","note":"Primary myelofibrosis","from":"primary-myelofibrosis","refs":["jak2","jak2-v617f"]},{"group":"history","date":"2005","precision":"year","title":"JAK2 V617F found in half of ET","note":"Essential thrombocythaemia (ET)","from":"essential-thrombocythaemia","refs":["jak2-v617f"]},{"group":"history","date":"2005","precision":"year","title":"Kerala screening trial shows visual inspection cuts oral cancer deaths in high-risk people","note":"Oral cavity cancer (mouth and tongue)","from":"oral-cavity-cancer","refs":[]},{"group":"history","date":"2005","precision":"year","title":"Kerala trial: visual screening cuts oral cancer deaths in high-risk people","note":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","from":"buccal-mucosa-cancer","refs":["kerala-oral-screening"]},{"group":"history","date":"2005","precision":"year","title":"Lenalidomide for del(5q)","note":"Myelodysplastic syndromes / neoplasms (MDS). Transfusion independence in two-thirds of del(5q) patients (List et al.).","from":"mds","refs":["lenalidomide"]},{"group":"history","date":"2005","precision":"year","title":"Lenalidomide produces transfusion independence in del(5q) MDS","note":"Lower-risk myelodysplastic syndromes","from":"mds-lower-risk","refs":["lenalidomide"]},{"group":"history","date":"2005","precision":"year","title":"Menin shown to be required by KMT2A fusion leukaemia","note":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","from":"aml-npm1-kmt2a","refs":["menin","kmt2a"]},{"group":"history","date":"2005","precision":"year","title":"MRC TE19: single-dose carboplatin equals radiotherapy in stage I","note":"Seminoma","from":"seminoma","refs":["carboplatin"]},{"group":"history","date":"2005","precision":"year","title":"New-onset diabetes after 50 carries a 1 percent three-year risk of pancreatic cancer","note":"Pancreatic ductal adenocarcinoma. Chari's Minnesota cohort of 2,122; observed-to-expected ratio 7.94.","from":"pancreatic","refs":["paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005","idea-pdac-new-onset-diabetes-risk-score-pathway"]},{"group":"history","date":"2005","precision":"year","title":"NPM1 mutations described in a third of adult AML","note":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","from":"aml-npm1-kmt2a","refs":["npm1"]},{"group":"history","date":"2005","precision":"year","title":"Nuclear beta-catenin and CTNNB1 mutations define adamantinomatous tumours","note":"Craniopharyngioma","from":"craniopharyngioma","refs":[]},{"group":"history","date":"2005","precision":"year","title":"PARP inhibition shown to kill BRCA-deficient cells (synthetic lethality)","note":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","from":"brca-palb2-pdac","refs":["parp-inhibitor","synthetic-lethality-map"]},{"group":"history","date":"2005","precision":"year","title":"Phoenix definition: nadir plus 2 ng/mL","note":"Biochemical recurrence of prostate cancer","from":"prostate-bcr","refs":["psa"]},{"group":"history","date":"2005","precision":"year","title":"PT-1: hydroxyurea beats anagrelide","note":"Essential thrombocythaemia (ET). In 809 high-risk patients hydroxyurea plus aspirin gave fewer arterial clots, less bleeding and less progression to myelofibrosis than anagrelide p...","from":"essential-thrombocythaemia","refs":["pt-1","hydroxyurea","anagrelide"]},{"group":"history","date":"2005","precision":"year","title":"Rituximab controversy","note":"HIV-associated (AIDS-related) lymphomas. AMC 010 shows excess infection deaths with rituximab at very low CD4; later analyses restrict the risk to CD4 under 50.","from":"hiv-associated-lymphoma","refs":["rituximab"]},{"group":"history","date":"2005","precision":"year","title":"Secondary KIT mutations identified as the mechanism of imatinib resistance (Antonescu, Heinrich)","note":"Imatinib-resistant GIST","from":"gist-imatinib-resistant","refs":["kit"]},{"group":"history","date":"2005","precision":"year","title":"SMARCB1/INI1 loss recognised","note":"Epithelioid sarcoma. Modena and colleagues link the tumour to SWI/SNF deficiency.","from":"epithelioid-sarcoma","refs":[]},{"group":"history","date":"2005","precision":"year","title":"Sorafenib and sunitinib open the anti-angiogenic era","note":"Clear cell renal cell carcinoma","from":"clear-cell-rcc","refs":["sunitinib"]},{"group":"history","date":"2005","precision":"year","title":"Sorafenib approved: first VEGF-pathway TKI in RCC","note":"Renal cell carcinoma","from":"rcc","refs":["antiangiogenic"]},{"group":"history","date":"2005","precision":"year","title":"Sorafenib/sunitinib: VEGF era","note":"Renal cell carcinoma","from":"rcc","refs":[]},{"group":"history","date":"2005","precision":"year","title":"Stupp regimen: temozolomide + RT","note":"Glioma & glioblastoma","from":"glioblastoma","refs":[]},{"group":"history","date":"2005","precision":"year","title":"Synthetic lethality of PARP inhibition in BRCA-deficient cells","note":"Ovarian cancer. Farmer and Bryant papers in Nature set up the PARP inhibitor era.","from":"ovarian","refs":["parp","synthetic-lethality"]},{"group":"history","date":"2005","precision":"year","title":"Synthetic lethality of PARP inhibition in BRCA-deficient cells","note":"Platinum-sensitive ovarian cancer","from":"platinum-sensitive-ovarian-cancer","refs":["parp-inhibitor","brca"]},{"group":"history","date":"2005","precision":"year","title":"Systematic profiling of SBA begins","note":"Small intestine cancer (small bowel adenocarcinoma). Registry analyses show the distinct site distribution and association with Crohn's, coeliac and FAP.","from":"small-bowel","refs":[]},{"group":"history","date":"2005","precision":"year","title":"Temozolomide chemoradiation becomes the glioblastoma standard","note":"Brain and spinal cord tumours (all types). The Stupp trial showed radiotherapy with concurrent and adjuvant temozolomide prolonged survival.","from":"brain-tumours","refs":["temozolomide"]},{"group":"journal","date":"2005","precision":"year","title":"Asia-Pacific journal of clinical oncology founded","note":"Wiley (Blackwell Publishing Asia)","from":"asia-pacific-journal-of-clinical-oncology","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"Cancer biomarkers founded","note":"SAGE Publications (formerly IOS Press)","from":"cancer-biomarkers","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"Clinical & translational oncology founded","note":"Springer","from":"clinical-and-translational-oncology","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"Clinical genitourinary cancer founded","note":"Elsevier","from":"clinical-genitourinary-cancer","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"Future oncology founded","note":"Taylor & Francis","from":"future-oncology","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"JCO Oncology Practice founded","note":"American Society of Clinical Oncology","from":"jco-oncology-practice","refs":[]},{"group":"journal","date":"2005","precision":"year","title":"Journal of cancer research and therapeutics founded","note":"Wolters Kluwer (Medknow Publications)","from":"journal-of-cancer-research-and-therapeutics","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","note":"Kralovics R, Passamonti F, Buser AS, et al. New England Journal of Medicine.","from":"paper-kralovics-n-engl-j-med","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"A pooled analysis of bone marrow micrometastasis in breast cancer","note":"Braun S, Vogl FD, Naume B, et al. New England Journal of Medicine.","from":"paper-braun-n-engl-j-med","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","note":"Pao W, Miller VA, Politi KA, et al. PLOS Medicine.","from":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"BRAF mutation in thyroid cancer","note":"Xing M. Endocrine-related cancer.","from":"paper-braf-thyroid-endocr-relat-cancer-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients","note":"Taixiang W, Munro AJ, Guanjian L. The Cochrane database of systematic reviews.","from":"paper-taixiang-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype","note":"Falini B, Mecucci C, Tiacci E, et al. New England Journal of Medicine.","from":"paper-falini-npm1-nejm-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","note":"Campbell PJ, Scott LM, Buck G, et al. The Lancet.","from":"paper-jak2-polycythaemia-vera-lancet-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Distinct sets of genetic alterations in melanoma","note":"Curtin JA, Fridlyand J, Kageshita T, et al. New England Journal of Medicine.","from":"paper-curtin-melanoma-genetic-alterations-nejm-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Dynamics of chronic myeloid leukaemia","note":"Michor F, Hughes TP, Iwasa Y, et al. Nature.","from":"paper-michor-nature","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Effect of screening on oral cancer mortality in Kerala, India","note":"Sankaranarayanan R, Ramadas K, Thomas G, et al. The Lancet.","from":"paper-sankaranarayanan-oral-screening-lancet-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","note":"Kobayashi S, Boggon TJ, Dayaram T, et al. New England Journal of Medicine.","from":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Genes that mediate breast cancer metastasis to lung","note":"Minn AJ, Gupta GP, Siegel PM, et al. Nature.","from":"paper-minn-nature","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","note":"Ren R. Nature Reviews Cancer.","from":"paper-ren-nat-rev-cancer","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma","note":"Oliver RT, Mason MD, Mead GM, et al. The Lancet.","from":"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with...","note":"Eberhard DA, Johnson BE, Amler LC, et al. Journal of Clinical Oncology.","from":"paper-kras-nsclc-j-clin-oncol-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","note":"Jain RK. Science.","from":"paper-jain-science","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Parkin 2005: Global cancer statistics, 2002","note":"Parkin DM, Bray F, Ferlay J, Pisani P. CA: A Cancer Journal for Clinicians.","from":"paper-parkin-global-cancer-statistics-2002-cacancer-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Probability of pancreatic cancer following diabetes: a population-based study","note":"Chari ST, Leibson CL, Rabe KG, et al. Gastroenterology.","from":"paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","note":"Tomlins SA, Rhodes DR, Perner S, et al. Science.","from":"paper-tomlins-tmprss2-ets-fusion-science-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","note":"Stupp R, Mason WP, van den Bent MJ, et al. New England Journal of Medicine.","from":"paper-stupp-temozolomide-nejm-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Tensional homeostasis and the malignant phenotype","note":"Paszek MJ, Zahir N, Johnson KR, et al. Cancer Cell.","from":"paper-paszek-cancer-cell","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","note":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. New England Journal of Medicine.","from":"paper-hera-b31-n9831-n-engl-j-med-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","note":"Romond EH, Perez EA, Bryant J, et al. New England Journal of Medicine.","from":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005","refs":[]},{"group":"paper","date":"2005","precision":"year","title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","note":"Kaplan RN, Riba RD, Zacharoulis S, et al. Nature.","from":"paper-kaplan-nature","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","note":"Cancer Cell","from":"ross-levine","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Adjuvant docetaxel for node-positive breast cancer (BCIRG 001)","note":"NEJM","from":"miguel-martin","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Antiviral defense by APOBEC3 Family Proteins","note":"Uirusu","from":"akifumi-takaori","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","note":"New England Journal of Medicine","from":"kenneth-anderson","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","note":"British Journal of Haematology","from":"sundar-jagannath","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Clinical features and prognostic factors of early breast cancer at a major cancer center in North India","note":"Indian Journal of Cancer","from":"raina-vinod","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO","note":"Annals of Oncology","from":"jean-yves-blay","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Consumption of Vegetables and Fruits and Risk of Breast Cancer","note":"JAMA","from":"carla-van-gils","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","note":"New England Journal of Medicine","from":"marco-vignetti","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Determination of the coding and non-coding nucleotide sequences of genuine Edmonston-Zagreb master seed and current working seed lot","note":"Vaccine","from":"dubravko-forcic","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial","note":"The Lancet","from":"sankaranarayanan-rengaswamy","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","note":"Lancet","from":"richard-gray","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomi...","note":"Lancet","from":"richard-peto","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Expression of DNA polymerase β cancer-associated variants in mouse cells results in cellular transformation","note":"Proceedings of the National Academy of Sciences","from":"joann-sweasy","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Galectin-1: a link between tumor hypoxia and tumor immune privilege","note":"JCO","from":"quynh-thu-le","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Gynecologic Cancer as a “Sentinel Cancer” for Women With Hereditary Nonpolyposis Colorectal Cancer Syndrome","note":"Obstetrics & Gynecology","from":"karen-lu","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)","note":"Blood","from":"thomas-kindler","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","note":"Nature Reviews Cancer","from":"brian-huntly","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Matrix Metalloproteinases as Therapeutic Targets in Cancer","note":"Current Cancer Drug Targets","from":"pia-vihinen","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","note":"NEJM","from":"monika-hegi","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism","note":"Nature","from":"gianvito-martino","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Noise in gene expression: origins, consequences, and control","note":"Science","from":"erin-oshea","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advance...","note":"International Journal of Radiation Oncology, Biology, Physics","from":"albert-koong","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative...","note":"JCO","from":"barbara-burtness","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Prevención de eventos cardiovasculares en hipertensos mayores de 65 años bajo el cuidado de un programa de control: Estudio de cohorte","note":"Anales de Medicina Interna","from":"esteban-langlois","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Proliferation Marker Ki-67 in Early Breast Cancer","note":"Journal of Clinical Oncology","from":"ander-urruticoechea","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","note":"NEJM","from":"roger-stupp","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas","note":"Journal of Clinical Oncology","from":"susana-puig","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","note":"Nature","from":"thomas-helleday","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Structural Basis for Tumor Pyruvate Kinase M2 Allosteric Regulation and Catalysis ,","note":"Biochemistry","from":"andrew-mesecar","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","note":"Immunity","from":"drew-weissman","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","note":"Nature","from":"chris-lord","refs":["alan-ashworth"]},{"group":"person-paper","date":"2005","precision":"year","title":"The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study","note":"Crit Care","from":"shlomi-codish","refs":[]},{"group":"person-paper","date":"2005","precision":"year","title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA)","note":"NEJM","from":"martine-piccart","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"Agent-based and multicellular simulations","note":"First use in humans or first approval, as the technology record states it.","from":"agent-based-tumour-models","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"Dose painting and biologically guided radiotherapy","note":"First use in humans or first approval, as the technology record states it.","from":"dose-painting","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","note":"First use in humans or first approval, as the technology record states it.","from":"in-room-imaging-systems","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","note":"First use in humans or first approval, as the technology record states it.","from":"intraoperative-fluorescence-imaging-systems","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"Single-use bioprocessing systems","note":"First use in humans or first approval, as the technology record states it.","from":"single-use-bioprocessing","refs":[]},{"group":"technology","date":"2005","precision":"year","title":"UGT1A1 genotyping before irinotecan","note":"First use in humans or first approval, as the technology record states it.","from":"ugt1a1-genotyping","refs":[]},{"group":"trial","date":"2005","precision":"year","title":"EORTC 26981 / NCIC CE.3 (Stupp trial) reported","note":"OS 14.6 vs 12.1 months, HR 0.63.","from":"eortc-26981","refs":["glioblastoma","temozolomide"]},{"group":"trial","date":"2005","precision":"year","title":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) reported","note":"B-31/N9831 10-year OS 84% vs 75.2%, HR 0.63.","from":"hera-b31-n9831","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab"]},{"group":"trial","date":"2005","precision":"year","title":"JBR.10 (NCIC CTG) reported","note":"Adjuvant vinorelbine and cisplatin prolonged disease-free and overall survival in completely resected stage IB to II disease; grade 3-4 neutropenia in 88 percent.","from":"jbr-10","refs":["resectable-nsclc","vinorelbine","cisplatin"]},{"group":"trial","date":"2005","precision":"year","title":"Kerala oral cancer visual screening trial (Trivandrum) reported","note":"Oral cancer mortality rate ratio 0.66 in tobacco/alcohol users after 3 rounds; 81% reduction in users who attended all 4 rounds at 15 years.","from":"kerala-oral-screening","refs":["head-and-neck","oral-cavity-cancer","buccal-mucosa-cancer"]},{"group":"trial","date":"2005","precision":"year","title":"PT-1 (Primary Thrombocythaemia 1) reported","note":"Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.57); more arterial clots, bleeding and myelofibrosis on anagrelide.","from":"pt-1","refs":["essential-thrombocythaemia","myeloproliferative-neoplasms","hydroxyurea","anagrelide"]},{"group":"regulatory","date":"2005-01-07","precision":"day","title":"Paclitaxel / nab-paclitaxel: approval (US)","note":"nab-Paclitaxel (Abraxane) for metastatic breast cancer","from":"paclitaxel","refs":[]},{"group":"regulatory","date":"2005-12-27","precision":"day","title":"Lenalidomide: approval (US)","note":"MDS del(5q)","from":"lenalidomide","refs":[]},{"group":"regulatory","date":"2005-12-28","precision":"day","title":"Letrozole (and other aromatase inhibitors): approval (US)","note":"Letrozole adjuvant indication","from":"letrozole","refs":[]}]},"route":"/years/2005/","neighbours":{"year":[{"id":"2004","kind":"year","name":"2004 in oncology","route":"/years/2004/"},{"id":"2006","kind":"year","name":"2006 in oncology","route":"/years/2006/"}]}}